title: Control of gastric acid secretion in health and disease.
abstract: Recent milestones in the understanding of gastric acid secretion and treatment of acid-peptic disorders include the (1) discovery of histamine H(2)-receptors and development of histamine H(2)-receptor antagonists, (2) identification of H(+)K(+)-ATPase as the parietal cell proton pump and development of proton pump inhibitors, and (3) identification of Helicobacter pylori as the major cause of duodenal ulcer and development of effective eradication regimens. This review emphasizes the importance and relevance of gastric acid secretion and its regulation in health and disease. We review the physiology and pathophysiology of acid secretion as well as evidence regarding its inhibition in the management of acid-related clinical conditions.
authors.affiliation: Department of Medicine, Division of Gastroenterology, Virginia Commonwealth University's Medical College of Virginia, McGuire Veterans Affairs Medical Center, Richmond, Virginia 23249, USA. Mitchell.Schubert@va.gov
authors.forename: Mitchell L
authors.initials: ML
authors.lastname: Schubert
authors.forename: David A
authors.initials: DA
authors.lastname: Peura
mesh_terms: D000109:Acetylcholine / Q000378:metabolism; D000818:Animals; D000897:Anti-Ulcer Agents / Q000009:adverse effects / Q000627:therapeutic use; D004063:Digestion; D004381:Duodenal Ulcer / Q000378:metabolism / Q000503:physiopathology; D004435:Eating; D005744:Gastric Acid / Q000378:metabolism*; D005753:Gastric Mucosa / Q000378:metabolism*; D005755:Gastrins / Q000378:metabolism; D005764:Gastroesophageal Reflux / Q000378:metabolism / Q000503:physiopathology; D005767:Gastrointestinal Diseases / Q000188:drug therapy / Q000378:metabolism* / Q000382:microbiology / Q000503:physiopathology; D017506:H(+)-K(+)-Exchanging ATPase / Q000378:metabolism; D016481:Helicobacter Infections / Q000378:metabolism / Q000503:physiopathology; D016480:Helicobacter pylori; D006632:Histamine / Q000378:metabolism; D006635:Histamine H2 Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007473:Ion Channels / Q000378:metabolism; D019899:Paracrine Communication; D054328:Proton Pump Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D013004:Somatostatin / Q000378:metabolism; D013270:Stomach / Q000187:drug effects / Q000201:enzymology / Q000294:innervation / Q000382:microbiology; D013276:Stomach Ulcer / Q000378:metabolism / Q000503:physiopathology
chemical_list: D000897:Anti-Ulcer Agents; D005755:Gastrins; D006635:Histamine H2 Antagonists; D007473:Ion Channels; D054328:Proton Pump Inhibitors; D013004:Somatostatin; D006632:Histamine; D017506:H(+)-K(+)-Exchanging ATPase; D000109:Acetylcholine